Posted by Michael Wonder on 17 Jul 2024
Longeveron announces US FDA grants fast track designation for Lomecel-B for the treatment of mild Alzheimer’s disease
17 July 2024 - Second designation received for Lomecel-B for the treatment of mild Alzheimer’s disease after regenerative medicine advanced therapeutics designation announced on 9 July 2024.
Longeveron today announced that the US FDA has granted fast track designation to Lomecel-B™ for the treatment of mild Alzheimer’s disease.
